ClinicalTrials.gg
CompletedNCT00446511Updated Jul 12, 2011Results posted

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

A Phase 3 interventional study of Valsartan and Enalapril in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-07-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
62nd of 139
250 · median 198
Started
2007
with 11 others
Phase 3
53 of 140
none open now
Registered
77th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 62nd largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 77th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this extension study is to compare the long-term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril alone in children with hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • children
  • pediatrics
  • high blood pressure
  • hypertension
  • valsartan
  • enalapril
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successful completion of 12 weeks of double-blind treatment in core protocol CVAL489K2302.
  • Patients participating in study CVAL489K2302 who may have discontinued prematurely due to uncontrolled hypertension defined as MSSBP > 20%, but \< 25% above the 95th percentile for age, gender, and height after visit 5, qualifies a patient for entry into this extension study.

Exclusion criteria

Exclusion Criteria:

  • Renal artery stenosis.
  • Current diagnosis of heart failure ( Class II-IV).
  • Second or third degree heart block without a pacemaker.
  • Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.
  • valvular heart disease.
  • Patient that demonstrates clinically significant abnormalities other than those associated with left ventricular hypertrophy and AV block controlled with a pacemaker.
  • Previous solid organ transplantation except renal, liver or heart transplantation. Renal, liver or heart transplant must have occurred at least 6 months prior to enrollment. Patient must be on stable doses of therapy for 3 months and deemed clinically stable by the investigator.
  • Patients who experienced any adverse events considered serious and drug related in protocol CVAL489K2302.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    CKD patients: Valsartan+enalapril

    Drug: Valsartan · Drug: Enalapril

  • Active comparator
    CKD patients: Enalapril

    Drug: Enalapril · Drug: placebo matched to valsartan

  • Experimental
    Non-CKD patients: Valsartan

    Drug: Valsartan · Drug: placebo matched to enalapril

  • Active comparator
    Non-CKD patients: Enalapril

    Drug: Enalapril · Drug: placebo matched to valsartan

Interventions

  • Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.

  • Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.

  • Drugplacebo matched to enalapril

    Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.

  • Drugplacebo matched to valsartan

    placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events

    Time frame: Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients)

Secondary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26

    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.

    Time frame: Core Baseline (Week 0) to Week 26

  2. Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26

    Systolic and diastolic blood pressure (BP) control was defined as msSBP and msDBP \< 95th percentile for gender, age, and height. After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.

    Time frame: Week 26

  3. Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20

    24-hour ambulatory blood pressure monitoring (ABPM) was conducted once during the extension in a subset of patients at selected centers. For all patients who completed a qualifying ABPM at baseline, an ABPM was to be performed at Week 20. The ABPM monitor was placed on the non-dominant arm.

    Time frame: Core Baseline (Week 0) to Week 20

  4. Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26

    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.

    Time frame: Core Baseline (Week 0) to Week 26

07

Results

Posted Jun 6, 2011
Limitations and caveats
Study was prolonged from 14 to 66 wks for CKD patients only. Most CKD patients completed the initial 14 wk extension period prior to amendment approval and the study was terminated prematurely with 3 CKD patients progressing to a maximum of Visit 13.

Participant flow

Participant flow — Overall Study
MilestoneCKD Patients: Valsartan+EnalaprilCKD Patients: EnalaprilNon-CKD Patients: ValsartanNon-CKD Patients: Enalapril
Started2117103109
Completed111596103
Not completed10276
Withdrew: Adverse event7231
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject0003
Withdrew: Administrative problems3041

Outcome measures

PrimaryNumber of Patients With Adverse Events
Time frame:
Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients)
Reported as:
Number · Participants
Number of Patients With Adverse Events
ParticipantsCKD Patients: Valsartan+EnalaprilCKD Patients: EnalaprilNon-CKD Patients: ValsartanNon-CKD Patients: Enalapril
Number of Patients With Adverse Events16115153
SecondaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26

After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.

Time frame:
Core Baseline (Week 0) to Week 26
Reported as:
Mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26
mmHgCKD Patients: Valsartan+EnalaprilCKD Patients: EnalaprilNon-CKD Patients: ValsartanNon-CKD Patients: Enalapril
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26-20.4 ± 11.48-11.7 ± 9.55-7.5 ± 8.47-7.2 ± 8.99
SecondaryPercentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26

Systolic and diastolic blood pressure (BP) control was defined as msSBP and msDBP \< 95th percentile for gender, age, and height. After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.

Time frame:
Week 26
Reported as:
Number · Percentage of patients
Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26
Percentage of patientsNon-CKD Patients: ValsartanNon-CKD Patients: Enalapril
Systolic BP control66.063.0
Diastolic BP control95.191.7
SecondaryChange From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20

24-hour ambulatory blood pressure monitoring (ABPM) was conducted once during the extension in a subset of patients at selected centers. For all patients who completed a qualifying ABPM at baseline, an ABPM was to be performed at Week 20. The ABPM monitor was placed on the non-dominant arm.

Time frame:
Core Baseline (Week 0) to Week 20
Reported as:
Mean · mmHg
Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20
mmHgCKD Patients: Valsartan+EnalaprilCKD Patients: EnalaprilNon-CKD Patients: ValsartanNon-CKD Patients: Enalapril
Systolic BP-23.3 ± 11.60-0.3 ± 14.42-11.5 ± 7.81-4.1 ± 11.49
Diastolic BP-17.8 ± 3.202.9 ± 10.81-12.2 ± 6.60-4.5 ± 7.59
SecondaryChange in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26

After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.

Time frame:
Core Baseline (Week 0) to Week 26
Reported as:
Mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26
mmHgCKD Patients: Valsartan+EnalaprilCKD Patients: EnalaprilNon-CKD Patients: ValsartanNon-CKD Patients: Enalapril
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26-23.6 ± 10.79-18.2 ± 9.51-11.6 ± 9.74-10.2 ± 9.70

Adverse events

Collected over Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CKD Patients: Valsartan+Enalapril—7/21 (33.3%)14/21 (66.7%)
Non-CKD Patients: Valsartan—1/103 (1%)25/103 (24.3%)
CKD Patients: Enalapril—0/17 (0%)11/17 (64.7%)
Non-CKD Patients: Enalapril—2/109 (1.8%)42/109 (38.5%)
Most frequent serious events
Most frequent serious events
EventCKD Patients: Valsartan+EnalaprilNon-CKD Patients: ValsartanCKD Patients: EnalaprilNon-CKD Patients: Enalapril
HyperkalaemiaMetabolism and nutrition disorders3/210/1030/170/109
Kidney transplant rejectionImmune system disorders1/210/1030/170/109
PyelonephritisInfections and infestations1/210/1030/170/109
White blood cell count decreasedInvestigations1/210/1030/170/109
SynostosisMusculoskeletal and connective tissue disorders1/210/1030/170/109
HypotensionVascular disorders1/210/1030/170/109
Adrenogenital syndromeCongenital, familial and genetic disorders0/211/1030/170/109
GastroenteritisInfections and infestations0/210/1030/171/109
SyncopeNervous system disorders0/210/1030/171/109
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCKD Patients: Valsartan+EnalaprilNon-CKD Patients: ValsartanCKD Patients: EnalaprilNon-CKD Patients: Enalapril
HyperkalaemiaMetabolism and nutrition disorders4/210/1032/173/109
HeadacheNervous system disorders4/2111/1031/1716/109
PyrexiaGeneral disorders3/215/1030/174/109
PharyngitisInfections and infestations2/217/1032/1711/109
CoughRespiratory, thoracic and mediastinal disorders1/212/1032/171/109
VomitingGastrointestinal disorders2/210/1030/173/109
Urinary tract infectionInfections and infestations2/211/1031/172/109
DizzinessNervous system disorders2/211/1030/171/109
HypotensionVascular disorders2/210/1030/170/109
NasopharyngitisInfections and infestations0/216/1031/179/109

Baseline characteristics

Age Continuous
Age Continuous(years)CKD Patients: Valsartan+EnalaprilCKD Patients: EnalaprilNon-CKD Patients: ValsartanNon-CKD Patients: EnalaprilTotal
Mean11.4 ± 3.4012.1 ± 3.0713.1 ± 2.7513.3 ± 2.8113.0 ± 2.89
Sex: Female, Male
Sex: Female, Male(Participants)CKD Patients: Valsartan+EnalaprilCKD Patients: EnalaprilNon-CKD Patients: ValsartanNon-CKD Patients: EnalaprilTotal
Female85412781
Male13126282169
08

Study locations

9 sites
  • Sites in USA
    East Hanover, New Jersey 07936, United States
  • Sites in Belgium
    Belgium, Belgium
  • Sites in France
    France, France
  • Sites in Germany
    Germany, Germany
  • Sites in Hungary
    Hungary, Hungary
  • Sites in India
    India, India
  • Sites in Italy
    Italy, Italy
  • Sites in Poland
    Poland, Poland
  • Sites in Turkey
    Turkey, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2007
First posted
Mar 13, 2007
Start
Jun 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Jun 6, 2011
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00446511
First posted
Mar 13, 2007
Start date
Jun 2007
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jun 6, 2011
Last update
Jul 12, 2011

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Enalapril

Start the discussion